Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-interferon therapy for essential thrombocythaemia.

F J Giles1, C R Singer, A G Gray

  • 1Department of Haematology, University College Hospital, London.

Lancet (London, England)
|July 9, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.

PloS one·2018
Same author

Multidrug Resistance in Acute Leukaemia: A Comparative Study of Immunocytochemical and RNA Slot Blot Detection of P-glycoprotein Expression.

Leukemia & lymphoma·2016
Same author

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Leukemia & lymphoma·2016
Same author

Unstable or High Risk Plaque: How Do We Approach It?

Medical journal, Armed Forces India·2016
Same author

Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease.

Blood cells, molecules & diseases·2013
Same author

A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.

Molecular genetics and metabolism·2013
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Recombinant alpha interferon effectively treated essential thrombocythaemia by lowering platelet counts and relieving symptoms in all patients. This therapy offers a safe, non-leukaemogenic alternative for essential thrombocythaemia management.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Essential thrombocythaemia is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • Symptomatic patients require effective and safe treatment options to manage disease complications.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of recombinant alpha interferon in patients with essential thrombocythaemia.
  • To determine if recombinant alpha interferon can safely reduce platelet counts and alleviate symptoms.

Main Methods:

  • A study involving 18 patients with symptomatic essential thrombocythaemia.
  • Treatment administered via subcutaneous dosage regimens of recombinant alpha interferon (2a or 2b).

Main Results:

Related Experiment Videos

  • All 18 patients experienced a selective reduction in platelet count.
  • Symptomatic relief was observed in all treated patients, regardless of prior treatment status.
  • The subcutaneous dosage regimens were well-tolerated.

Conclusions:

  • Recombinant alpha interferon demonstrates significant efficacy in managing essential thrombocythaemia.
  • This therapeutic agent provides a well-tolerated and non-leukaemogenic treatment option.
  • Recombinant alpha interferon is a promising alternative therapy for essential thrombocythaemia.